Neuromodulation in polycystic ovary syndrome

Obstetrics and Gynecology Clinics of North America

Volumn 28, Issue 1, 2001, Pages 35-62

  Kalro, Brinda N ^a,b   Loucks, Tammy L ^c   Berga, Sarah L ^a,b  

^a SLB) ^*  (United States)

^b SLB)   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALANIN; LEPTIN; NEUROPEPTIDE Y; OPIATE; SOMATOMEDIN C;

CATECHOLAMINE RELEASE; HORMONE RELEASE; HUMAN; HYPOPHYSIS FUNCTION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; METABOLIC ACTIVATION; NEUROMODULATION; NEUROTRANSMITTER RELEASE; OVARY POLYCYSTIC DISEASE; OVULATION; PARACRINE SIGNALING; PRIORITY JOURNAL; PULSE GENERATOR; REVIEW;

EID: 0035083953     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(05)70184-4     Document Type: Article

References (207)

1. Le virilisme pilaire et son association a l'insuffisance glycolytique (diabete des femmes a barb)
2. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells
3. Role of leptin in the neuroendocrine response to fasting
4. Human fetal development: Role of fetal ovaries
5. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: Relevance to the developmental phase of polycystic ovary syndrome
6. Rapid and profound suppression of messenger ribonucleic acid encoding follicle-stimulating hormone beta by inhibin from primate Sertoli cells
7. Regulation of porcine granulosa cell steroidogenic acute regulatory protein (StAR) by insulin-like growth factor I: Synergism with follicle-stimulating hormone or protein kinase A agonist
8. A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with the polycystic ovary syndrome
9. Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa
10. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome
11. Changes in β-endorphin content of discrete hypothalamic nuclei during the estrous cycle of the rat
12. Modulation of luteinizing hormone immunoreactivity and bioactivity by dopamine but not epinephrine in women
13. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: Evidence for perinatal masculinization of neuroendocrine function in women
14. Immunocytochemical detection of insulin in rat hypothalamus and its possible uptake from cerebrospinal fluid where it possibly mediates food intake
15. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone
16. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome
17. Increased luteinizing hormone and α-subunit secretion in women with hyperandrogenic ovulation
18. Neuropeptide Y stimulates luteinizing hormone-releasing hormone release from superfused hypothalamic GT1-7 cells
19. Gonadotropin-releasing hormone regulates follicle-stimulating hormone-beta gene expression through an activin/follistatin autocrine or paracrine loop
20. Opiatergic control of LH secretion is eliminated by gonadectomy
21. Histochemical localization of nitric oxide neurons in the hypothalamus: Association with gonadotropin-releasing hormone neurons and co-localization with N-methyl-D-aspartate receptors
22. Identification and terminal distribution of the tubero-hypophyseal monoamine fibre systems in the rat by means of stereotaxic and microspectrofluorimetric techniques
23. Endorphins and the regulation of human menstrual cycle
24. Twenty-four-hour luteinizing hormone and follicle-stimulating hormone secretory patterns in gonadal dysgenesis
25. Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome
26. Cloning and expression of a rat D2 dopamine receptor cDNA
27. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
28. Inhibin, activin, and follistatin: Regulation of follicle-stimulating hormone messenger ribonucleic acid levels
29. In vivo regulation of FSH synthesis by inhibin and activin
30. Novel B219/OB receptor isoforms: Possible role of leptin in hematopoiesis and reproduction
31. Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity
32. Evidence for an autocrine role of activin B within rat anterior pituitary cultures
33. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome
34. The frequency of gonadotropin-releasing hormone stimulation differentially regulates gonadotropin subunit messenger ribonucleic acid expression
35. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation
36. The role of the insulin-like growth factors in the central nervous system
37. The isolation and physiology of inhibin and related proteins
38. Hormonal effects of flutamide in young women with polycystic ovary syndrome
39. Follistatin and activin: A potential intrinsic regulatory system within diverse tissues
40. Estradiol is selectively neurotoxic to hypothalamic β-endorphin neurons
41. Clinical and biological phenotypes in late-onset 21-hydroxylase deficiency
42. Circhoral oscillations of plasma LH in the ovariectomized rhesus monkey
43. Interaction of insulin-like growth factor-I and estradiol signaling pathways on hypothalamic neuronal differentiation
44. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood
45. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with polycystic ovary syndrome
46. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
47. Contribution of plasma homovanillic acid (HVA) to urine and cerebrospinal fluid HVA in the monkey and its pharmacokinetic disposition
48. Control of pulsatile LH release in male rats
49. Physiologic basis of ovulation induction
50. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y
51. Role of astroglia and insulin-like growth factor-1 in gonadal hormone-dependent synaptic plasticity
52. Inhibition of luteinizing hormone release by dopamine infusion in healthy women and in various pathophysiological conditions
53. Dopamine might not be involved in the pathogenesis of polycystic ovary syndrome
54. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: A molecular study
55. Gonadal steroids and opioid control of gonadotropin secretion in man
56. Polycystic ovary syndrome: A changing perspective
57. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals
58. Catecholamines in the hypothalamus and the pituitary gland
59. Peripheral catecholamine alterations in adolescents with polycystic ovary syndrome
60. β-Endorphin and β-lipotropin plasma levels in hirsute women: Correlation with body weight
61. Neurovascular link between neurohypophysis and adenohypophysis
62. The opioid control of LH and FSH release: Effects of a met-enkephalin analogue and naloxone
63. Opiate mediation of emnorrhea in hyperprolactinemia and weight-loss related amenorrhea
64. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women
65. Influence of gonadotropin-releasing hormone pulse amplitude, frequency, and treatment duration on the regulation of luteinizing hormone (LH) subunit messenger ribonucleic acids and LH secretion
66. Induction of ovulation in rabbit by electrical stimulation of hypothalamo-hypophyseal mechanism
67. Oestrous rhythm, pseudopregnancy and pituitary stalk in rat
68. Functional grafts of anterior pituitary gland
69. Title of article
70. Regulation of galanin secretion from pituitary cells in vitro by estradiol and GHRH
71. Autoradiographic localization of insulin receptors in olfactory and limbic areas
72. Insulin-like growth factor I. A possible metabolic signal involved in the regulation of female puberty
73. Organization of LHRH cells: Differential apposition of neurotensin, substance P and catecholamine axons
74. c-Fos and related immediate early gene products as markers of activity in neuroendocrine systems
75. Cerebellar monoamine nerve terminals, a new type of afferent fibers to the cortex cerebelli
76. Induction of gene expression of the catecholamine-synthesizing enzymes by insulin-like growth factor I
77. The nocturnal rise of plasma testosterone in pubertal boys
78. Inhibition of gonadotropin and prolactin release by dopamine: Effect of endogenous estradiol levels
79. The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release
80. Follistatin gene expression in the pituitary: Localization in gonadotropes and folliculostellate cells in diestrous rats
81. Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone-releasing hormone discharge
82. Hypophysial portal vessel infusion: In vivo demonstration of LRF, FRF, and PIF in pituitary stalk plasma
83. Effect of insulin-like growth factor I on gonadotropin release from the hypothalamus-pituitary axis in vitro
84. Positive and negative feedback control by estrogen of luteinizing hormone secretion in the rhesus monkey
85. Effects of a potent antagonist to gonadotropin-releasing hormone on male rats: Luteinizing hormone is suppressed more than follicle-stimulating hormone
86. Circulating luteinizing hormone pulse frequency in women with polycystic ovary syndrome
87. The effect of morphine on the electrophysiological activity of the hypothalamic luteinizing hormone pulse generator in the Rhesus monkey
88. On the control of gonadotropin secretion in the Rhesus monkey
89. Activin-binding protein is present in pituitary
90. Measuring turnover of neurotransmitters in human brain
91. Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome
92. Changes in the pituitary and hypothalamic content of methionine-enkephalin during the estrous cycle of rats
93. The inhibitory effect of dopamine agonists on LH release in women
94. The insulin-like growth factor (IGF) system and gonadotropin regulation: Actions and interactions
95. Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome
96. Serum leptin levels in women with polycystic ovary syndrome: The role of insulin resistance/hyperinsulinemia
97. Abnormal splicing of the leptin receptors in diabetic mice
98. 2 receptor gene haplotypes with anovulation and fecundity in female hispanics
99. Possible contribution of brain peptides to the development of eating disorders and obesity
100. Gonadal steroids and hypothalamic galanin and neuropeptide Y: Role in eating behavior and body weight control in female rats
101. Role of GnRH drive in the pathophysiology of polycystic ovary syndrome
102. Simultaneous measurement of luteinizing hormone (LH)-releasing hormone, LH, and follicle-stimulating hormone release in intact and short-term castrate rats
103. Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?
104. Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women
105. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome
106. The control of bioactive luteinizing hormone secretion in women with polycystic syndrome
107. Mid-follicular phase pulses of inhibin B are absent in polycystic ovary syndrome and are initiated by successful laparoscopic ovarian diathermy: A possible mechanism regulating emergence of the dominant follicle
108. Endogenous galanin modulates the gonadotropin and prolactin proestrous surges in the rat
109. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?
110. Hypothalamic changes in norepinephrine release in rats with estradiol valerate-induced polycystic ovaries
111. Estimates of dopamine and serotonin synthesis by the awake human brain
112. Absence of mutations in the human OB gene in obese/diabetic subjects
113. Leptin concentrations in the polycystic ovary syndrome
114. Dopaminergic mechanisms and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women
115. Transient effects of L-5-hydroxytryptophan on pituitary function in men and women
116. Gonadal and extragonadal expression of inhibin alpha, beta A, and beta B subunits in various tissues predicts diverse functions
117. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: Common and distinct features
118. Endocrine effects of naloxone-induced opiate receptor blockade
119. Impairment of dopaminergic and opioidergic activity in patients with polycystic ovarian disease is restored by treatment for the induction of ovulation
120. Functional restitution of pituitary grafts re-transplanted from kidney to median eminence
121. Follicle-stimulating hormone beta subunit messenger ribonucleic acid concentrations during the rat estrous cycle
122. The impact of reversible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty
123. The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome
124. Polycystic ovary syndrome: Evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone
125. Gonadal steroid modulation of naloxone-induced luteinizing hormone secretion in the rat
126. Impairment of opioid control of luteinizing hormone secertion in menstrual disorders
127. Chronic administration of neuropeptide Y into the lateral ventricle starting at 30 days of life delays sexual maturation in the female rat
128. A striking difference in the gonadotropin response to gonadectomy during infantile development in the rhesus monkey (Macaca mulatta)
129. Estradiol modulates insulin-like growth factor I receptors and binding proteins in neurons from the hypothalamus
130. Hypophysial-portal vessels and their colloid accompaniment
131. Estradiol coupling to endothelial nitric oxide stimulates gonadotropin-releasing hormone release from rat median eminence via a membrane receptor
132. Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microedenoma
133. Evidence for increased dopammergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea
134. The role of endogenous opiates on LH secretion during the menstrual cycle
135. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome
136. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome
137. Effects of exogenous β-endorphin on pituitary hormone secretion in normal human subjects
138. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women
139. Immunoneutralization of endogenous inhibin modifies hormone secretion and ovulation rate in the rat
140. Effect of recombinant inhibin on luteinizing hormone and follicle-stimulating hormone secretion in the rat
141. Production and regulation of inhibin subunits in pituitary gonadotropes
142. Inhibin/activin subunits are costored with FSH and LH in secretory granules of the rat anterior pituitary gland
143. Estrogen increases proenkephalin messenger ribonucleic acid levels in the ventromedial hypothalamus of the rat
144. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: An in situ hybridization study
145. Endogenous opiates modulate pulsatile luteinizing hormone release in humans
146. The dopaminergic inhibition of LH secretion during the menstrual cycle
147. Further evidence against dopamine deficiency as the cause of inappropriate gonadotropin secretion in patients with polycystic ovary syndrome
148. Induction of galanin gene expression in gonadotropin-releasing hormone neurons with puberty in the rat
149. Relative changes in LH pulsatility during the menstrual cycle: Using data from hypogonadal women as a reference point
150. Involvement of gamma amino butyric acid (GABA) in the postnatal function of the GnRH pulse generator as determined on the basis of GnRH and GnRH-receptor gene expression in the hypothalamus and the pituitary
151. Serum leptin concentrations in women with polycystic ovary syndrome
152. Expression of c-fos protein in brain: Metabolic mapping at the cellular level
153. Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue
154. Episodic luteinizing hormone secretion in man: Pulse analysis, clinical interpretation, physiologic mechanisms
155. Estradiol is concentrated in tyrosine hydroxylase containing neurons of the hypothalamus
156. Inhibition of ovulation in rabbit by adrenergic-blocking agent dibenamine
157. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice
158. Bromocriptine response in normoprolactinemic patients with polycystic ovary disease: A preliminary report
159. Increased dopamine turnover in women with polycystic ovary syndrome
160. Dopamine-norepinephrine interaction in hyperactive boys treated with d-amphetamine
161. Evidence for altered catecholamine metabolism in polycystic ovary syndrome
162. Molecular biology of dopamine receptors
163. Molecular neurobiology of dopaminergic receptors
164. Are circulating leptin and luteinizing hormone synchronized in patients with polycystic ovary syndrome?
165. Episodic leptin release is independant of leutinizing hormone secretion
166. Detection of LH release from individual pituitary cells by the reverse plaque assay: Estrogen increases the fraction of gonadotropes responding to GnRH
167. The effect of naloxone on endogenous opiod regulation of pituitary gonadoropins and prolactin during the menstrual cycle
168. Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotropin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro
169. Modulation of anterior pituitary luteinizing hormone response to gonadotropin-releasing hormone by insulin-like growth factor I in vitro
170. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women
171. Effects of increasing the frequency of low doses of gonadotropin-releasing hormone (GnRH) on gonadotropin secretion in GnRH-deficient men
172. The effect of bromocriptine in the polycystic ovary syndrome
173. Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity
174. Amenorrhea associated with bilateral polycystic ovaries
175. The role of neuropeptide Y in the antiobesity action of the obese gene product
176. Life without neuropeptide Y
177. Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease
178. Identification and expression cloning of a leptin receptor, OB-R
179. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome
180. Control of luteinizing hormone-releasing hormone pulse generation in non-human primates
181. Effects of ovary suppression by a long-acting GnRH-agonist on circulating GH, insulin-like growth factor I and insulin levels in women with polycystic ovary syndrome
182. Insulin receptors in the central nervous system: Localization, signaling mechanisms and functional aspects
183. Insulin receptors in the pituitary gland: Morphological evidence for influence on opioid peptide-synthesizing cells
184. Pulsatile patterns of gonadotropin release; effects of sleep and pharmacological agents
185. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: Indirect evidence of a partial gonadotroph desensitization
186. Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity
187. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man
188. Effect of sex steroids on β-endorphins in hypophyseal portal blood
189. β-Endorphin in hypophyseal portal blood: Variations throughout the menstrual cycle
190. Evidence for a major role of inhibin in the feedback control of FSH in the male rat
191. Synaptology of luteinizing hormone-releasing hormone neurons in rat preoptic area
192. Morphology of luteinizing hormone-releasing hormone neurons as a function of age and hormonal condition in the male rat
193. Elevated levels of plasma β-endorphin and melanocyte stimulating hormone in polycystic ovary syndrome
194. An interactive physiological role of neuropeptide Y and galanin in pulsatile pituitary luteinizing hormone secretion
195. Inappropriate secretion of follicle-stimulating hormone neurons in rat preoptic area
196. Morphology of luteinizing hormone-releasing hormone neurons as a 194
197. Ultradian fluctuations of gonadotropins
198. Causal relationship between the hormonal variables in the menstrual cycle
199. The operating characteristics of the hypothalamic-pituitary system during the menstrual cycle and observations of biological action of somatostatin
200. Prolactin in human reproduction
201. Inhibins, activins, and follistatins: Gonadal proteins modulating the secretion of follicle-stimulating hormone
202. Further evidence concerning catecholamine metabolism in polycystic ovary syndrome following GnRH administration
203. Role of leptin in hypothalamic-pituitary function
204. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity
205. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle
206. Positional cloning of the mouse obese gene and its human homologue